Ascendis Pharma AS

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 1529.82, 2228.37, 2721.54, 3374.87, 3781.3 ], "ebit_estimate": [ 360.17, 847.31, 1287.02, 1659.98, 1964.71 ], "ebitda_estimate": [ 440.39, 906.12, 1219.67, null, null ], "net_income_estimate": [ 1062.39, 737.61, 1107.22, 1367.83, 1582.82 ], "per_share_eps_estimate": [ 16.11, 11.03, 16.48, 20.57, 23.56 ], "eps_nri_estimate": [ 16.36, 11.05, 16.41, 20.57, 23.56 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 1.42, 11.92, 31.4, null, null ], "pretax_income_estimate": [ 315.05, 823.27, 1245.39, 1632.31, 1952.77 ], "operating_cash_flow_per_share_estimate": [ 17.14, 16.94, 20.22, null, null ], "roa_estimate": [ 55.9, 21.7, 28.3, null, null ], "roe_estimate": [ 391.58, 129.02, 64.29, null, null ], "gross_margin_estimate": [ 89.63, 89.43, 89.5, 89.5, 89.5 ], "operating_cash_flow_estimate": [ 1106.18, 1092.92, 1304.73, null, null ], "pettm_estimate": [ 16.79, 24.53, 16.41, 13.15, 11.48 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "48.69", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 48.69, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -33.13, "future_gross_margin_estimate_growth": 0.89, "future_operating_cash_flow_per_share_estimate_growth": 144.99 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 379.85, 405.78, 470.09, 478.83, 554.58, 608.41, 669.33 ], "ebit_estimate": [ 67.55, 105.57, 146.55, 172.46, 224.37, 267.18, 315.14 ], "ebitda_estimate": [ 145.47, 122.88, 151.74, 163.9, null, null, null ], "net_income_estimate": [ 88.66, 91.37, 138.19, 152.95, 178.12, 215.8, 255.77 ], "per_share_eps_estimate": [ 1.25, 1.38, 2.03, 2.08, 2.71, 3.28, 3.88 ], "eps_nri_estimate": [ 1.48, 1.3, 2.03, 2.19, 2.71, 3.28, 2.59 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 95.29, 95.86, 144.63, 167.03, 203.81, 247.77, 295.16 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 87.67, 89.33, 88.5, 95, 95, 95, 95 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 40.21, 33.02, 26.8, 22.64, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "48.69", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 48.69, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -33.13, "future_gross_margin_estimate_growth": 0.89, "future_operating_cash_flow_per_share_estimate_growth": 144.99 }